Quarterly report pursuant to Section 13 or 15(d)

Accrued Expenses and Other Long-Term Liabilities - Components of Accrued Expenses and Other Long-Term Liabilities (Detail)

v3.10.0.1
Accrued Expenses and Other Long-Term Liabilities - Components of Accrued Expenses and Other Long-Term Liabilities (Detail) - USD ($)
$ in Thousands
Jun. 30, 2018
Dec. 31, 2017
Accrued Expenses:    
Professional fees $ 1,535 $ 1,625
Salaries, bonuses and related benefits 3,569 5,279
Accrued expenses - related party 73 95
Research and development 5,143 4,046
Dr. Falk Pharma milestone 3,365 3,059
Accrued royalties payable 1,268 1,411
Deferred coupon funding 1,777 1,087
Other 779 1,030
Total accrued expenses 17,509 17,632
Other long-term liabilities:    
Deferred rent and long-term lease abandonment charge 4,987 4,739
Total other long-term liabilities $ 4,987 $ 4,739